Lisata Therapeutics shares rise 13.51% after-hours as company regains certepetide rights in Greater China via Qilu agreement termination.

Lisata Therapeutics surged 13.51% in after-hours trading following the mutual termination of its license agreement with Qilu Pharmaceutical for certepetide in the Greater China region, which granted the company full development rights to the drug. The termination, effective January 23, 2026, revoked Qilu’s exclusive rights and potential $200 million in milestone payments and royalties, but Lisata’s CEO emphasized regaining control as a strategic advantage. Additionally, the company announced a $4.00-per-share acquisition offer by Kuva Labs, representing an 85% premium over its recent closing price, which could unlock significant shareholder value. These developments, combined with strong Q3 2025 earnings that exceeded estimates and a robust balance sheet, fueled investor optimism. The stock’s rally reflects confidence in Lisata’s renewed focus on certepetide’s development and the attractive acquisition terms, despite the loss of prior revenue opportunities from the terminated partnership.